Nasdaq GlobeNewswire

Karolinska Development – Q4 and 2015 Year-End Report – February 2016


Jim Van heusden, CEO, comments: “During the course of 2015 we have made significant progress in executing our new strategy which is designed to transform Karolinska Development into a successful Nordic Venture Capital company delivering attractive returns to our shareholders.In 2015 we have focused our portfolio and streamlined our own organization accordingly I look forward to updating you on our progress in the course of 2016 when we will look to build future value by making new investments.”

2015 – Full Year Highlights

  • Jim Van heusden appointed CEO in March 2015

  • Launched new strategy focused on transforming Karolinska Development into a leading Nordic Venture Capital Company

  • New organizational structure put in place to support venture capital strategy

  • Modified deal flow agreement with Karolinska Institutet Holding AB (KIHAB) will allow Karolinska Development to invest in more mature companies and create a more balanced Nordic-centric investment portfolio

  • Streamlined the Karolinska Development portfolio to allow resources to be focused on those companies with the best chances of delivering attractive returns to shareholders

  • Adoption of a more representative approach to reporting the fair value in line with  the International Private Equity and Venture Capital (IPEV) valuation guidelines

  • Total of SEK 204 million invested in portfolio companies with SEK 131 million coming from Karolinska Development and SEK 73 million from external investors. This is in line with Karolinska Development’s new approach of attracting third party investors to support the development of its portfolio companies.  Another SEK 70 million was raised by third-party syndicates for divested companies Pharmanest, XSpray Microparticles and Athera Biotechnologies.

  • Current level of funding provides sufficient runway to execute its strategy and to unlock the potential value of its portfolio

Q4 Highlights

  • The difficult market environment has also impacted our portfolio and resulted in a non-realized decrease of the Fair Value in line with our valuation guidelines. Total Fair Value of the portfolio at year end was SEK 591.7 million, a decrease of SEK 130.8 million compared to the end of third quarter. Net Fair Value of the portfolio at year end was SEK 267.7 million, a decrease of SEK 83.3 million compared to the end of the third quarter

  • Continuing to execute our strategy, which is focused on transforming Karolinska Development into a leading Nordic Venture Capital Company

  • Karolinska Development and Karolinska Institutet Holding AB (KIHAB) announced the signing of a new non-exclusive deal flow agreement in December. This new agreement will allow Karolinska Development to invest in more mature companies and increase its focus on building a more balanced investment portfolio by sourcing opportunities from both KI and other academic institutions across the Nordic region

  • In December, the Company appointed Viktor Drvota, M.D. PhD as Chief Investment Officer. Dr Drvota is an experienced life science investor and joins Karolinska Development from SEB Venture Capital, where he has been Head of Life Science since 2002. At the same time it was announced that Terje Kalland, M.D. PhD, the Company’s Deputy Chief Executive Officer and Chief Scientific Officer, would retire from both positions effective December 31, 2015

  • Further focusing of the investment portfolio with the divestment of the Company’s entire shareholding in Athera Biotechnologies AB to a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Industrifonden in an earn-out agreement

Portfolio Developments – Q4 Highlights

  • Dilaforette initiated a Phase II clinical trial in October with sevuparin in patients with sickle-cell disease (SCD) experiencing a vaso-occlusive crisis. The trial results are anticipated in H2 2016

  • In October, Promimic signed a strategic agreement with Amendia Inc. (US) that will allow Amendia to develop Promimic’s HAnano Surface technology for use with its patient-focused spinal implants

  • Aprea presented updated preliminary data from its ongoing Phase Ib/II clinical study in ovarian cancer at the European Society for Gynaecological Oncology congress (ESGO) in Nice, France, in October. The data presented suggest that APR-246 can be combined with standard chemotherapy and that preliminary efficacy data indicate that the combination regimen has activity in the treatment of recurrent ovarian cancer

  • OssDsign raised SEK 93 million in an equity financing led by new investors SEB Venture Capital and Fouriertransform with continued investment from Karolinska Development. The proceeds will be used for the market expansion of OssDsign’s product line of unique craniofacial implants

Post period events

  • In January, Akinion Pharmaceuticals AB, announced the appointment of Dr Richard Jones as Chief Executive Officer. Dr Jones recently served at Novartis and GSK as VP, Global Haematology Medicines Commercialization Leader

  • In January, Promimic announced that its strategic partner Sistema de Implante Nacional (SIN) had initiated the launch of the first dental implant coated with Promimic's implant surface HAnano Surface. The implant was launched at CIOSP (Sao Paolo International Dental Meeting), the second largest dental trade show in the world.

  • In February, Dilaforette signed an agreement with Arabian Gulf University to support the company’s current Phase II clinical trial with sevuparin in patients with SCD

Financial Update

  • Investments in portfolio companies during the fourth quarter amounted to SEK 15.7 million (SEK 27.5 million  2014). A total of SEK 130.8 million was invested in portfolio companies during the course of 2015 (SEK 92.6 million  2014)

  • Net loss amounted to SEK 121.6 million in the fourth quarter (SEK - 46.8 million in the fourth quarter 2014)

  • Cash, cash equivalents and short term liquidity investments decreased by SEK 31.2 million during the fourth quarter and amounted to SEK 297.2 million as of end December 2015. At the end of 2014 cash, cash equivalents and short term liquidity investments amounted to SEK141.3 million

  • The difficult market environment has also impacted our portfolio and resulted in a non-realized decrease of the Fair Value in line with our valuation guidelines. Total Fair Value of the portfolio at year end was SEK 591.7 million, a decrease of SEK 130.8 million compared to the end of third quarter. Net Fair Value of the portfolio at year end was SEK 267.7 million, a decrease of SEK 83.3 million compared to the end of the third quarter

  • Restructured organization is expected to reduce operational cost in 2016 by approximately 30%

Conference Call and Webcast

Please dial in at one of the following numbers a few minutes before the start of the conference call:

  • From Sweden: +46 (0) 8 505 564 74
  • From the US: +1 855 753 22 30
  • From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:

Host: Jim Van heusden, CEO. 

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: 

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail:


About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30Pressemelding

SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with

Marcus Hiles - Texas Takes #1 Four Years in a Row in America's Top States for Business19.7.2018 23:39Pressemelding

DALLAS, July 19, 2018 (GLOBE NEWSWIRE) -- The future business scene in Texas is looking brighter than ever as the state continues to hold its place as a national leader. Growth is spreading across areas such as North Texas, Houston and San Antonio with businesses quickly expanding their operations in the state that offers some of the best in business-friendly climates and overall growth potential. Tapping into the market recently are global leaders such as Toyota, Liberty Mutual and JP Morgan who have taken advantage of the state's increasing network of commercial properties, workforce and business resources. Named by CNBC for the fourth consecutive year as America's Top State for Business, Texas scored above all 50 states on overall business competitiveness. With the business hub building on its role as a national leader for the past decade, this top rank title reflects the progress Texas has made in cementing its place in the global economy. "This national recognition comes without s

Second Quarter 2018 Results Conference Call19.7.2018 21:34Pressemelding

AURORA, Ontario, July 19, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) SECOND QUARTER 2018 RESULTS CONFERENCE CALL WEDNESDAY - AUGUST 8th, 2018 7:30 AM ET DIAL IN NUMBERS North America Toll Free: International Toll: Webcast: 1-888-223-4641 1-416-981-9080 Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until August 15, 2018 North America Toll Free: International Toll: Reservation No.: 1-800-558-5253 1-416-626-4100 21892829 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations, 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations, 905-726-7108 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originali

Uganda National Airlines Company Limited Signs Firm Order for Four Bombardier CRJ900 Aircraft19.7.2018 18:36Pressemelding

First operator of the new CRJ Series ATMOSPHÈRE cabin in Africa MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that it has signed a firm order for four new CRJ900 regional jets with Uganda National Airlines Company. Based on the list price for the CRJ900 aircraft, the firm order is valued at approximately US$190 million. "We congratulate the Government of Uganda for the revival of its national flag carrier, and are thrilled that the new airline has selected Bombardier and the CRJ900 regional jets for its upcoming debut," said Jean-Paul Boutibou, Vice President, Sales, Middle-East and Africa, Bombardier Commercial Aircraft. "Recognized for its superior economics and efficiency, the CRJ Series aircraft have enabled airlines worldwide to serve communities with better connectivity, and we look forward to supporting the development of Uganda's regional air travel with these CRJ900 regional jets." Uganda Airlines will operate the CRJ900 in dual-cla

CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology19.7.2018 15:03Pressemelding

"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies" SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL). The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models wil

Jumio Introduces Liveness Detection for Web to Better Deter Fraud During Account Onboarding19.7.2018 14:00Pressemelding

New identity proofing functionality ensures that the person behind a Web upload verification is present and the person actually creating a new online account PALO ALTO, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Jumio, the creator of Netverify(TM) Trusted Identity as a Service (TIaaS), today announced the addition of Liveness Detection for Web to better thwart fraudsters' evolving and sophisticated attempts to assume another individual's identity. With identity verification, Jumio's approach is to first verify the government-issued ID (e.g., driver's license, passport or ID card) and ensure that it is authentic and has not been doctored. For mobile SDK customers, Jumio then requires the user to take a selfie which enables the company to compare the person in the selfie to the person pictured in the ID document. Since Netverify is an omnichannel solution, Jumio also supports identity verification via desktop webcams. This channel enables our customers to reach large market segments who a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom